Tax thread runs through pharma deals

Apr 07, 2014

“Even before the Treasury proposals were announced, there was a huge amount of interest in doing these deals because they can create millions in cost savings.”

- Christopher Cox, co-chair of Cadwalader’s Corporate Group, commenting in the Financial Times regarding the surge in “inversions,” whereby a company uses an overseas transaction to relocate its headquarters, since the U.S. government revealed plans to tighten the rules allowing U.S. companies to re-domicile their tax base. Cox, who advised Ireland’s Elan on its $8.6 billion inversion deal with Perrigo last year, added, however, that the pace of enquiries by U.S. companies has stepped up markedly in the past six weeks.

CadwaladerSpotlight

February 4 | PLI's CMBS and the Real Estate Lawyer 2019: Lender and Borrower Issues in the Capital Market | New York

Jeffrey Rotblat will discuss "Accumulation/Aggregation/Alternative Exit Strategies" at this event.

Cadwalader's research and intelligence platform provides analysis on changes in U.S. financial regulation. Subscribers receive a daily newsletter interpreting new laws, rules and enforcement actions that impact financial institutions.